Real-World Effectiveness and Safety of SDZ-ADL (Adalimumab Biosimilar) in Patients with Psoriasis from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)

SDZ-ADL is a biosimilar of reference adalimumab. Here, the safety and effectiveness data from British Association Dermatologists Biologic Immuno-modulators Register (BADBIR) are reported. In set, were compared with conventional systemics data. quality-of-life patients treated as first-time biologic, or who switched previous biologic to SDZ-ADL, assessed using Psoriasis Activity Severity Index (PASI) Dermatology Life Quality (DLQI), respectively. A total 565 (incidence rate (IR) per 1000 person-years 29.1, 95% CI 26.8–31.6) serious infections 48 (IR 2.5, 1.8–3.3) myocardial infarction events reported in cohort four 31.5, 8.6–80.7) one 7.9, 0.2–43.9) cohort, One patient (0.7% (1/136)) injection-site pain cohort. At 12 months, PASI ≤ 2 was achieved 84.6% (11/13) 76.9% (10/13) DLQI 0/1 70% (7/10) 75% (3/4) biologic-naïve biologic-switch cohorts, After year therapy, 82.7% (110/133) remained on SDZ-ADL. well-tolerated effective psoriasis.